Search Results - "E O Ignatova"

Lessons from the routine tumor molecular profiling in Russia by Mileyko, V., Rozhavskaya, E., Veselovsky, E., Kovtun, A., Ivanov, M., Ignatova, E.O.

Get full text

Epigenomics paves a new way to assess potential toxicity and chemotherapeutic response of breast tumours to 5-fluorouracil by Strelnikov, V.V., Ignatova, E.O., Kekeeva, T.V., Poddubskaya, E.V., Nemtsova, M.V., Kuznetsova, E.B., Zaletaev, D.V., Tanas, A.S.

Get full text

Leukotriene B4 receptors as a therapeutic target for triple-negative breast cancer by Kalinkin, A.I., Strelnikov, V.V., Ignatova, E.O., Kekeeva, T.V., Nemtsova, M.V., Zaletaev, D.V., Poddubskaya, E.V., Kuznetsova, E.B., Tanas, A.S.

Get full text

Molecular portrait of stomach cancer associated with the Epstein–Barr virus by Ignatova, E. O., Seryak, D. A., Fedyanin, M. Yu, Tryakin, A. A., Pokataev, I. A., Menshikova, S. F., Vakhabova, Yu. V., Karbyshev, M. S., Smirnova, K. V., Tulyandin, S. A.

“…Epstein–Barr virus (EBV) associated gastric carcinoma is a special form of gastric adenocarcinoma that arises against the background of clonal growth of…”
Get full text

Genotyping of BRCA1, BRCA2, and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips by Nasedkina, T. V., Gromyko, O. E., Emelyanova, M. A., Ignatova, E. O., Kazubskaya, T. P., Portnoi, S. M., Zasedatelev, A. S., Lyubchenko, L. N.

“…The identification of BRCA1/2 and CHEK2 germline mutations is central to the molecular diagnostics of susceptibility to breast or/and ovarian cancer. A…”
Get full text

Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips by Nasedkina, T V, Gromyko, O E, Emel'ianova, M A, Ignatova, E O, Kazubskaia, T P, Portnoĭ, S M, Zasedatelev, A S, Liubchenko, L N

“…Germline mutations of BRCA1/2 genes cause the predisposition of their carriers to breast or/and ovary cancers (BC or/and OC) during the lifetime…”
Get more information

Analysis of Circulating Tumor Cells in Patients with Triple Negative Breast Cancer during Preoperative Chemotherapy by Lavrov, A. V., Zubtsova, Zh. I., Zubtsov, D. A., Frolova, M. A., Ignatova, E. O., Skrypnikova, M. A., Malysheva, E. V., Legchenko, E. V., Petrovskii, A. V., Utyashev, I. A., Tyulyandin, S. A., Gol’dshtein, D. V.

“…The presence of circulating tumor cells in the blood of patients with triple negative breast cancer (early and locally advanced cancer) before and after…”
Get full text

Discordance of estrogen receptor status between primary and metastatic breast cancer--possible reasons and prognostic value by Bogush, T A, Popova, A S, Dudko, E A, Ignatova, E O, Polotskiĭ, B E, Tiuliandin, S A, Davydov, M I

“…The aim of the review was systematization of the data on discordance in expression of estrogen receptors between primary and metastatic breast cancer,…”
Get more information

Toxicity and efficacy of biosimilar bevacizumab in the second-line therapy for metastatic colon cancer in routine clinical practice: results of an independent observational study by M.   Yu. Fedyanin, F.   V. Moiseenko, M.   A. Lyadova, V.  N.  Vorobyeva, V.  V.  Petkau, A.  V.  Fateeva, E.  S.  Kuzmina, O.  Yu.  Novikova, V.   A. Chubenko, N.  Kh.  Abduloeva, A.  A.  Kudryavtsev, E.   O. Ignatova, R.   R. Shakirov, O.  A.  Pardabekova, L.  V.  Kindyalova, S.  P.  Pelikh, O.   A. Gladkov, S.  A.  Tjulandin, A.  A.  Tryakin

“…Objective: to compare the efficacy and tolerability of second‑line chemotherapy with original bevacizumab (Avastin) and biosimilar bevacizumab produced by…”
Get full text

45PLessons from the routine tumor molecular profiling in Russia by Mileyko, V, Rozhavskaya, E, Veselovsky, E, Kovtun, A, Ivanov, M, Ignatova, E O

Get full text

78PLeukotriene B4 receptors as a therapeutic target for triple-negative breast cancer by Kalinkin, A I, Strelnikov, V V, Ignatova, E O, Kekeeva, T V, Nemtsova, M V, Zaletaev, D V, Poddubskaya, E V, Kuznetsova, E B, Tanas, A S

Get full text

34PEpigenomics paves a new way to assess potential toxicity and chemotherapeutic response of breast tumours to 5-fluorouracil by Strelnikov, V V, Ignatova, E O, Kekeeva, T V, Poddubskaya, E V, Nemtsova, M V, Kuznetsova, E B, Zaletaev, D V, Tanas, A S

Get full text

Design of Marker Panels for Prediction of Neoadjuvant Chemotherapy Response of Triple-Negative Breast Tumors Based on the Results of Genome-Wide DNA Methylation Screening by Kalinkin, A. I., Sigin, V. O., Ignatova, E. O., Frolova, M. A., Kuznetsova, E. B., Vinogradov, I. Y., Vinogradov, M. I., Vinogradov, I. I., Nemtsova, M. V., Zaletaev, D. V., Tanas, A. S., Strelnikov, V. V.

“…The rate of complete pathomorphological response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer is low and ranges from 30 to 40%. At the…”
Get full text

Discordance of Estrogen Receptor Status Between Primary and Metastatic Breast Cancer: Possible Reasons and Prognostic Value by T. A. Bogush, A. S. Popova, E. A. Dudko, E. O. Ignatova, B. E. Polotsky, S. A. Tjuljandin, M. I. Davydov

“…The aim of the review was systematization of the data on discordance in expression of estrogen receptors between primary and metastatic breast cancer,…”
Get full text

Bioequivalence assessment of BCD-022 (trastuzumab, manufactured by JSC BIOCAD, Russia) as compared with Herceptin® (F.Hoffmann-La Roche Ltd., Switzerland), used in combination with paclitaxel in HER2-positive metastatic breast cancer patients: findings of the international, double-blind phase III clinical study by E O Ignatova, O N Burdaeva, M V Kopp, B N Kotiv, D P Udovitsa, D L Stroiakovskii, S M Alekseev, L P Sheveleva, A V Khorinko, Iu S Shapovalova, V M Moiseenko, R A Ivanov

“…Objective. Within the multi-center double-blind randomized clinical study, investigate the bioequivalence (immediate efficacy, safety and pharmacokinetics) of…”
Get full text

Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study by M. Yu. Fedyanin, Kh. Kh.-M. El’sunkaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, V. A. Aliev, D. V. Kuzmichev, Z. Z. Mamedli, M. V. Chernykh, V. V. Glebovskaya, S. I. Tkachev, N. A. Kozlov, S. A. Tjulandin

“…Objective: to evaluate the prognostic value of clinical and pathomorphological stages in patients with rectal cancer after preoperative chemoradiotherapy and…”
Get full text

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status by M. Yu. Fedyanin, Kh. Kh.-M. El’snukaeva, I. A. Pokataev, A. A. Tryakin, A. A. Bulanov, O. V. Sekhina, D. A. Chekini, E. O. Ignatova, S. S. Gordeev, M. D. Budurova, Z. Mamedli, D. V. Podluzhnyy, N. A. Kozlov, S. A. Tyulyandin

“…Objective: to determine the efficacy of 2 oxaliplatin-based chemotherapy regimens (FOLFOX and XELOX) for metastatic colorectal cancer (CRC) depending on the…”
Get full text